After Golden Cross, Agenus (AGEN)'s Technical Outlook is Bright
After reaching an important support level, Agenus Inc. (AGEN) could be a good stock pick from a technical perspective. AGEN recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
Agenus: Big On BOT/BAL As Cash Burn And Catalysts Collide
I remain cautiously optimistic about Agenus, driven by BOT/BAL's strong clinical data and cost-reduction efforts, but maintain a speculative 2/5 conviction rating. The BOT/BAL program shows promising efficacy in MSS colorectal cancer, potentially resetting the standard of care and offering a significant commercial opportunity. Agenus's restructuring, asset monetization, and cost cuts aim to extend the runway and avoid near-term dilution, but financial risks and execution remain key concerns.
Despite Fast-paced Momentum, Agenus (AGEN) Is Still a Bargain Stock
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Agenus (AGEN) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Agenus Inc. (AGEN) Q1 2025 Earnings Call Transcript
Agenus Inc. (NASDAQ:AGEN ) Q1 2025 Earnings Conference Call May 12, 2025 8:30 AM ET Company Participants Zack Armen - Head of Investor Relations Garo Armen - Chairman and CEO Steven O'Day - Chief Medical Officer Robin Taylor - Chief Commercial Officer Richard Goldberg - Chief Development Officer Christine Klaskin - VP Finance and Principal Financial and Accounting Officer Conference Call Participants Emily Bodnar - H.C. Wainwright Mayank Mamtani - B.
Agenus (AGEN) Reports Q1 Loss, Tops Revenue Estimates
Agenus (AGEN) came out with a quarterly loss of $1.03 per share versus the Zacks Consensus Estimate of a loss of $1.61. This compares to loss of $3.04 per share a year ago.
Agenus (AGEN) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Agenus (AGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why Agenus (AGEN) Is a Great 'Buy the Bottom' Stock Now
Agenus (AGEN) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Agenus Inc. (AGEN) Q4 2024 Earnings Call Transcript
Agenus Inc. (NASDAQ:AGEN ) Q4 2024 Earnings Conference Call March 11, 2025 8:30 AM ET Company Participants Zack Armen - Head of Investor Relations, Corporate Development Garo Armen - Chairman and Chief Executive Officer Christine Klaskin - Vice President, Finance and Principal Financial and Accounting Officer Steven O'Day - Chief Medical Officer Robin Taylor - Chief Commercial Officer Conference Call Participants Emily Bodnar - H.C. Wainwright Mayank Mamtani - B.
Agenus (AGEN) Reports Q4 Loss, Lags Revenue Estimates
Agenus (AGEN) came out with a quarterly loss of $2.04 per share versus the Zacks Consensus Estimate of a loss of $2.36. This compares to loss of $2.60 per share a year ago.
Is Agenus (AGEN) Stock Outpacing Its Medical Peers This Year?
Here is how Agenus (AGEN) and ANIXA BIOSCIENCES INC (ANIX) have performed compared to their sector so far this year.
Agenus (AGEN) Is Attractively Priced Despite Fast-paced Momentum
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Agenus (AGEN) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Are Medical Stocks Lagging Agenus (AGEN) This Year?
Here is how Agenus (AGEN) and Concentra Group (CON) have performed compared to their sector so far this year.
